Status:
UNKNOWN
Serum Cysteine Rich Protein 61 and Cystatin C for Early Detection of Acute Kidney Injury in Patients With Heart Diseases
Lead Sponsor:
Assiut University
Conditions:
Acute Kidney Injury
Eligibility:
All Genders
18-90 years
Brief Summary
Acute Kidney Injury (AKI) is defined as an absolute increase in serum creatinine ≥0.3 mg/dl (≥26.4 μmol/l), a percentage increase in serum creatinine ≥50% (1.5-fold from baseline), or a reduction in u...
Detailed Description
Cystatin C (CysC), a cystatin protease inhibitor, is less affected by non-specific factors. When glomerular filtration rate (GFR) decreases, CysC begins to increase. CysC was recommended to be measur...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- Informed consent
- Patient with absolute increase in serum creatinine ≥0.3 mg/dl (≥26.4 μmol/l) or with percentage increase in serum creatinine ≥50% (1.5-fold from baseline)
- Patient with reduction in urine output (documented oliguria \< 0.5 ml/kg/hour for \> 6 hours)
- Patient with typical chest pain, ECG changes, Echocardiogram positive finding
Exclusion
- History of nephrectomy
- patient with renal transplantation
- patient with renal replacement therapy initiated before admission
- patient with chronic kidney disease
- patient on regular haemodialysis
- patient known to be diabetic
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT05242705
Start Date
March 1 2022
End Date
December 31 2024
Last Update
March 8 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.